{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:09:01Z","timestamp":1766167741299,"version":"3.48.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"F\u0131rat University Scientific Research Project Center","award":["TF.22.26."],"award-info":[{"award-number":["TF.22.26."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-025-03780-3","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:41:53Z","timestamp":1758948113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of topical ramucirumab in experimental corneal neovascularization model"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8627-121X","authenticated-orcid":false,"given":"Mustafa","family":"B\u00fclb\u00fcl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1704-9719","authenticated-orcid":false,"given":"Onur","family":"\u00c7atak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8857-994X","authenticated-orcid":false,"given":"Murat","family":"Erda\u011f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9874-3838","authenticated-orcid":false,"given":"Tuncay","family":"Kulo\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3237-3672","authenticated-orcid":false,"given":"Serhat","family":"Han\u00e7er","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"key":"3780_CR1","unstructured":"Binder P LRM. Anatomical considerations for contact lens fitting in Contact Lenses. Kastl P, (ed). Kendall: Hunt Publishing Company, 1995:1-118."},{"key":"3780_CR2","unstructured":"Wilhelmus K, Huang A, Hwwang D, Parrish C, Sutpuin J WJ. External Disease and Cornea Basic Science Course. Am Acad Ophthalmol. 2000;8(11-13-54)."},{"key":"3780_CR3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.exer.2004.07.008","volume":"79","author":"B Klenkler","year":"2004","unstructured":"Klenkler B, Sheardown H (2004) Growth factors in the anterior segment: role in tissue maintenance, wound healing and ocular pathology. Exp Eye Res 79:677\u2013688","journal-title":"Exp Eye Res"},{"issue":"5","key":"3780_CR4","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1600-0420.2004.00312.x","volume":"82","author":"L Gan","year":"2004","unstructured":"Gan L, Fagerholm P, Palmblad J (2004Oct) Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 82(5):557\u201363","journal-title":"Acta Ophthalmol Scand"},{"issue":"9","key":"3780_CR5","first-page":"2514","volume":"41","author":"P Wolfgang","year":"2000","unstructured":"Wolfgang P, Speicher L, Humpel C (2000) Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41(9):2514\u20132522","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3780_CR6","first-page":"264","volume":"104","author":"DTA Corneal","year":"2006","unstructured":"Corneal DTA (2006) Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 104:264\u2013302","journal-title":"Trans Am Ophthalmol Soc"},{"key":"3780_CR7","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00003226-198706040-00004","volume":"6","author":"RJ Epstein","year":"1987","unstructured":"Epstein RJ, Stulting RD, Hendricks RL et al (1987) Corneal neovascularization. Pathogenesis and inhibition. Cornea 6:250\u2013257","journal-title":"Cornea"},{"key":"3780_CR8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11010-013-1840-2","volume":"386","author":"I Prasadam","year":"2014","unstructured":"Prasadam I, Zhou Y, Du Z, Chen J, Crawford R, Xiao Y (2014) Osteocyte-induced angiogenesis via VEGF\u2013MAPK-dependent pathways in endothelial cells. Mol Cell Biochem 386:15\u201325","journal-title":"Mol Cell Biochem"},{"issue":"9","key":"3780_CR9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0968-0004(03)00193-2","volume":"28","author":"MJ Cross","year":"2003","unstructured":"Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L (2003) VEGF-receptor signal transduction. Trends Biochem Sci 28(9):488\u201394","journal-title":"Trends Biochem Sci"},{"issue":"2","key":"3780_CR10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/01.RES.0000233356.10630.8a","volume":"99","author":"R Inoue","year":"2006","unstructured":"Inoue R, Jensen LJ, Shi J, Morita H, Nishida M, Honda A, Ito Y (2006) Transient receptor potential channels in cardiovascular function and disease. Circ Res 99(2):119\u2013131","journal-title":"Circ Res"},{"issue":"12","key":"3780_CR11","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1161\/01.RES.0000171894.03801.03","volume":"96","author":"D Jho","year":"2005","unstructured":"Jho D, Mehta D, Ahmmed G, Gao XP, Tiruppathi C, Broman M, Malik AB (2005) Angiopoietin1 opposes VEGF- induced increase in endothelial permeability by inhibiting TRPC1- dependent Ca2 influx. Circ Res 96(12):1282\u20131290","journal-title":"Circ Res"},{"key":"3780_CR12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0143-4160(03)00057-5","volume":"33","author":"AL Perraud","year":"2003","unstructured":"Perraud AL, Schmitz C, Scharenberg AM (2003) TRPM2 Ca2+ permeable cation channels: from gene to biological function. Cell Calcium 33:519\u2013531","journal-title":"Cell Calcium"},{"issue":"4","key":"3780_CR13","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1161\/ATVBAHA.114.304802","volume":"35","author":"M Mittal","year":"2015","unstructured":"Mittal M, Urao N, Hecquet CM, Zhang M, Sudhahar V, Gao XP, Komarova Y, Ushio-Fukai M, Malik AB (2015) Novel role of reactive oxygen species-activated Trp melastatin channel-2 in mediating angiogenesis and postischemic neovascularization. Arterioscler Thromb Vasc Biol 35(4):877\u201387","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"3780_CR14","first-page":"502","volume":"17","author":"AD Mendelsohn","year":"1986","unstructured":"Mendelsohn AD, Stock EL, Lo GG, Schneck GL (1986Aug) Laser photocoagulation of feeder vessels in lipid keratopathy. Ophthalmic Surg. 17(8):502\u20138 (PMID: 2427984)","journal-title":"Ophthalmic Surg."},{"issue":"3","key":"3780_CR15","first-page":"291","volume":"36","author":"S Goto","year":"1992","unstructured":"Goto S (1992) Q-switched Nd:YAG laser treatment for corneal neovascularization. Jpn J Ophthalmol. 36(3):291\u2013300 (PMID: 1464968)","journal-title":"Jpn J Ophthalmol."},{"issue":"4","key":"3780_CR16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/ICO.0b013e3182542613","volume":"32","author":"M Papathanassiou","year":"2013","unstructured":"Papathanassiou M, Theodoropoulou S, Analitis A, Tzonou A, Theodossiadis PG (2013) Vascular endothelial growth factor inhibitors for treatment of corneal neovascularization: a meta-analysis. Cornea 32(4):435\u201344","journal-title":"Cornea"},{"issue":"1","key":"3780_CR17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00417-002-0591-7","volume":"241","author":"PC Wu","year":"2003","unstructured":"Wu PC, Liu CC, Chen CH, Kou HK, Shen SC, Lu CY, Chou WY, Sung MT, Yang LC (2003) Inhibition of experimental angiogenesis of cornea by somatostatin. Graefes Arch Clin Exp Ophthalmol 241(1):63\u20139","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"3780_CR18","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1034\/j.1600-0420.1999.770404.x","volume":"77","author":"T Demir","year":"1999","unstructured":"Demir T, Celiker UO, K\u00fckner A, Mogulko\u00e7 R, Celebi S, Celiker H (1999Aug) Effect of Octreotide on experimental corneal neovascularization. Acta Ophthalmol Scand 77(4):386\u201390","journal-title":"Acta Ophthalmol Scand"},{"issue":"12","key":"3780_CR19","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1001\/archopht.118.12.1666","volume":"118","author":"Y Qian","year":"2000","unstructured":"Qian Y, Dekaris I, Yamagami S, Dana MR (2000) Topical soluble tumor necrosis factor receptor type I suppresses ocular chemokine gene expression and rejection of allogeneic corneal transplants. Arch Ophthalmol 118(12):1666\u201371","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"3780_CR20","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/archopht.120.8.1063","volume":"120","author":"BK Ambati","year":"2002","unstructured":"Ambati BK, Joussen AM, Ambati J, Moromizato Y, Guha C, Javaherian KGS, O\u2019Reilly MS, Adamis AP (2002Aug) Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol. 120(8):1063\u20138","journal-title":"Arch Ophthalmol."},{"issue":"11","key":"3780_CR21","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s004170050387","volume":"237","author":"AM Joussen","year":"1999","unstructured":"Joussen AM, Kruse FE, V\u00f6lcker HE, Kirchhof B (1999Nov) Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol 237(11):920\u20137","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"3780_CR22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","volume":"27","author":"I Bahar","year":"2008","unstructured":"Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A (2008) Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27(2):142\u20137","journal-title":"Cornea"},{"key":"3780_CR23","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s40265-014-0244-2","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole RM, Vaidya A (2014) Ramucirumab: first global approval. Drugs 74:1047\u20131058","journal-title":"Drugs"},{"key":"3780_CR24","doi-asserted-by":"crossref","unstructured":"Franklin MC, Navarro EC, Wang Y, Patel S, Singh P, Zhang Y et all. The structural basis for the function of two anti-VEGF receptor 2 antibodies. Structure. 2011 Aug 10;19(8):1097-107.","DOI":"10.1016\/j.str.2011.01.019"},{"issue":"3","key":"3780_CR25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40265-020-01263-6","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY (2020) Ramucirumab: a review in hepatocellular carcinoma. Drugs 80(3):315\u2013322","journal-title":"Drugs"},{"key":"3780_CR26","volume":"41","author":"MT Eski","year":"2022","unstructured":"Eski MT, Teberik K, Oltulu P, Ankaral\u0131 H, Kaya M, Alpay M (2022) The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization. Hum Exp Toxicol 41:9603271221084674","journal-title":"Hum Exp Toxicol"},{"issue":"2","key":"3780_CR27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.sjopt.2017.02.008","volume":"31","author":"T Al-Debasi","year":"2017","unstructured":"Al-Debasi T, Al-Bekairy A, Al-Katheri A, Al Harbi S, Mansour M (2017) Topical versus subconjunctival anti-vascular endothelial growth factor therapy (bevacizumab, ranibizumab and aflibercept) for treatment of corneal neovascularization. Saudi J Ophthalmol 31(2):99\u2013105","journal-title":"Saudi J Ophthalmol"},{"key":"3780_CR28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000322061","volume":"46","author":"MN Hashemian","year":"2011","unstructured":"Hashemian MN, Z-Mehrjardi H, Moghimi S (2011) Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats. Ophthalmic Res 46:50\u201354","journal-title":"Ophthalmic Res"},{"issue":"16","key":"3780_CR29","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2147\/CMAR.S447549","volume":"24","author":"A Bozdag","year":"2024","unstructured":"Bozdag A, Kuloglu T, Artas G, Aydin S (2024Apr) Investigation of Trpa1 and Trpc1 Immunreactivities in Colon Adenocarcinomas. Cancer Manag Res. 24(16):377\u2013384","journal-title":"Cancer Manag Res."},{"key":"3780_CR30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archopht.126.1.71","volume":"126","author":"BO Bachmann","year":"2008","unstructured":"Bachmann BO, Bock F, Wiegand SJ et al (2008) Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol 126:71\u20137","journal-title":"Arch Ophthalmol"},{"key":"3780_CR31","doi-asserted-by":"crossref","unstructured":"Photodynamic effect of a new photosensitizer ATX-S10 on corneal neovascularization. Exp Eye Res 1998; 67: 313-22. Gohto Y, Obana A, Kaneda K, al.","DOI":"10.1006\/exer.1998.0527"},{"key":"3780_CR32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.sjopt.2017.02.008","volume":"31","author":"T Al-Debasi","year":"2017","unstructured":"Al-Debasi T, Al-Bekairy A, Al-Katheri A, Al Harbi S, Mansour M (2017) Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization. Saudi J Ophthalmol 31:99\u2013105","journal-title":"Saudi J Ophthalmol"},{"key":"3780_CR33","doi-asserted-by":"crossref","unstructured":"Jamaludin MI, Wan Abdul Halim WH, Cheng TC. Clinical Outcomes of Topical Bevacizumab for the Treatment of Corneal Neovascularization. Cureus. 2024 May 2;16(5):e59548.","DOI":"10.7759\/cureus.59548"},{"issue":"5","key":"3780_CR34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jfo.2024.104152","volume":"47","author":"M Rocher","year":"2024","unstructured":"Rocher M, Benayoun Y, Quilbe S, Laribi S, Fournie P, Leveziel N, Trone MC, Bourcier T, Robert PY (2024Apr 4) \u00c9tude randomis\u00e9e de l\u2019injection sous-conjonctivale de b\u00e9vacizumab (Avastin\u00ae) dans la n\u00e9o-vascularisation corn\u00e9enne [A randomized study of subconjonctival bevacizumab (Avastin\u00ae) injection for corneal neovascularization]. J Fr Ophtalmol. 47(5):10","journal-title":"J Fr Ophtalmol."},{"key":"3780_CR35","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1590\/S0001-37652007000300004","volume":"79","author":"LF Barros","year":"2007","unstructured":"Barros LF, Belfort-Jr R (2007) The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc 79:389\u2013394","journal-title":"An Acad Bras Cienc"},{"key":"3780_CR36","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00417-008-0976-3","volume":"247","author":"YS Han","year":"2009","unstructured":"Han YS, Lee JE, Jung JW, Lee JS (2009) Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 247:541\u2013548","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3780_CR37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","volume":"27","author":"I Bahar","year":"2008","unstructured":"Bahar I, Kaiserman I, McAllum P, Franzco MB, Rootman D, Slomovic A (2008) Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27:142\u2013147","journal-title":"Cornea"},{"key":"3780_CR38","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1755-3768.2009.01571.x","volume":"88","author":"Z Habot-Wilner","year":"2010","unstructured":"Habot-Wilner Z, Barequet IS, Ivanir Y, Moisseiev J, Rosner M (2010) The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Acta Ophthalmol 88:862\u2013867","journal-title":"Acta Ophthalmol"},{"key":"3780_CR39","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","volume":"247","author":"Y Koenig","year":"2009","unstructured":"Koenig Y, Bock F, Horn F et al (2009) Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin\u00ae) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 247:1375\u20131382","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3780_CR40","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.2147\/OTT.S61132","volume":"7","author":"G Aprile","year":"2014","unstructured":"Aprile G, Rijavec E, Fontanella C, Rihawi K, Grossi F (2014) Ramucirumab: preclinical research and clinical development. Onco Targets Ther 7:1997\u20132006","journal-title":"Onco Targets Ther"},{"issue":"8","key":"3780_CR41","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.str.2011.01.019","volume":"19","author":"MC Franklin","year":"2011","unstructured":"Franklin MC, Navarro EC, Wang Y et al (2011) The structural basis for the function of two anti-VEGF receptor 2 antibodies. Structure 19(8):1097\u2013107","journal-title":"Structure"},{"issue":"2","key":"3780_CR42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jtos.2012.01.005","volume":"10","author":"W Stevenson","year":"2012","unstructured":"Stevenson W, Cheng SF, Dastjerdi MH, Ferrari G, Dana R (2012) Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf 10(2):67\u201383","journal-title":"Ocul Surf"},{"key":"3780_CR43","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","volume":"57","author":"JH Chang","year":"2012","unstructured":"Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT (2012) Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol 57:415\u2013429","journal-title":"Surv Ophthalmol"},{"issue":"8","key":"3780_CR44","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/10520295.2017.1371333","volume":"92","author":"S Altan","year":"2017","unstructured":"Altan S, Sa\u011fs\u00f6z H, O\u011furtan Z (2017) Topical dimethyl sulfoxide inhibits corneal neovascularization and stimulates corneal repair in rabbits following acid burn. Biotech Histochem 92(8):619\u2013636","journal-title":"Biotech Histochem"},{"issue":"3","key":"3780_CR45","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/15569527.2020.1760877","volume":"39","author":"H Yildirim","year":"2020","unstructured":"Yildirim H, Aydemir O, Balbaba M, \u00d6zercan \u0130H, \u0130lhan N (2020) Comparison of the effect of topical bevacizumab and sorafenib in experimental corneal neovascularization. Cutan Ocul Toxicol 39(3):223\u2013228","journal-title":"Cutan Ocul Toxicol"},{"key":"3780_CR46","doi-asserted-by":"crossref","unstructured":"\u00c7elenk M, Y\u0131ld\u0131r\u0131m H, Tektemur A, Balbaba M, Erda\u011f. Effect of topical motesanib in experimental corneal neovascularization model. Int Ophthalmol. 2023 Aug;43(8):2989-2997.","DOI":"10.1007\/s10792-023-02685-3"},{"key":"3780_CR47","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s12026-012-8373-8","volume":"55","author":"H Knowles","year":"2013","unstructured":"Knowles H, Li Y, Perraud AL (2013) The TRPM2 ion channel, an oxidative stress and metabolic sensor regulating innate immunity and inflammation. Immunol Res 55:241\u2013248","journal-title":"Immunol Res"},{"key":"3780_CR48","doi-asserted-by":"crossref","unstructured":"Huang P, Qu C, Rao Z, Wu D Zhao J. Bidirectional regulation mechanism of TRPM2 channel: role in oxidative stress, inflammation and ischemia-reperfusion injury. Front Immunol. 2024 Jun 28;15:1391355.","DOI":"10.3389\/fimmu.2024.1391355"},{"issue":"Pt 1","key":"3780_CR49","volume":"284","author":"YS Li","year":"2025","unstructured":"Li YS, Ren HC, Li H, Xing M, Cao JH (2025) From oxidative stress to metabolic dysfunction: the role of TRPM2. Int J Biol Macromol 284(Pt 1):138081","journal-title":"Int J Biol Macromol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03780-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03780-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03780-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:04:47Z","timestamp":1766167487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03780-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3780"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03780-3","relation":{},"ISSN":["1573-2630"],"issn-type":[{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2025,9,27]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in compliance with the ARVO Statement on the Use of Animals in Ophthalmic and Vision Research. The study protocols were approved by the F\u0131rat University Experimental Animal Studies Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}}],"article-number":"394"}}